Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: A randomized placebo-controlled trial

Menopause

Volumn 20, Issue 10, 2013, Pages 1020-1026

  Davison, Sonia L ^a   Bell, Robin J ^a   Robinson, Penelope J ^a   Jane, Fiona ^a   Leech, Jennifer ^b   Maruff, Paul ^b,c   Egan, Gary F ^a,b   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Scientific Division   (Australia)

Author keywords

Cognition; Drospirenone; Estradiol; Functional magnetic resonance imaging; Menopause; Women

Indexed keywords

DROSPIRENONE PLUS ESTRADIOL; PLACEBO;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESTROGEN DEFICIENCY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; MENTAL CAPACITY; OCCIPITAL LOBE; OXYGEN BLOOD LEVEL; PARIETAL LOBE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; VAGINA BLEEDING;

ANDROSTENES; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; COGNITION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; UTERINE HEMORRHAGE;

EID: 84885177870     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318287474f     Document Type: Article

References (42)

1. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54: 2072-2077.
2. Janicki SC, Schupf N. Hormonal influences on cognition and risk for Alzheimer's disease. Curr Neurol Neurosci Rep 2010;10: 359-366.
3. Sullivan Mitchell E, Fugate Woods N. Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study. J Womens Health (Larchmt) 2001;10: 351-362.
4. Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, Geller SE. Objective hot flashes are negatively related to verbal memory performance in midlife women. Menopause 2008;15: 848-856.
5. Maki PM. Minireview: effects of different HT formulations on cognition. Endocrinology 2012;153: 3564-3570.
6. Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebocontrolled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 2006;13: 411-422.
7. Wroolie TE, Kenna HA, Williams KE, et al. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17A-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry 2011;19: 792-802.
8. Alhola P, Tuomisto H, Saarinen R, Portin R, Kalleinen N, Polo-Kantola P. Estrogen + progestin therapy and cognition: a randomized placebocontrolled double-blind study. J Obstet Gynaecol Res 2010;36: 796-802.
9. Silverman DH, Geist CL, Kenna HA, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 2011;36: 502-513.
10. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69: 163-169.
11. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288: 2123-2129.
12. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76: 103-105.
13. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17A-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15: 816-822.
14. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59: 60-70.
15. Davison SL, Bell RJ, Gavrilescu M, et al. Testosterone improves verbal learning and memory in postmenopausal women: results from a pilot study. Maturitas 2011;70: 307-311.
16. Gogos A, Gavrilescu M, Davison S, et al. Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: an fMRI study. Neuropsychologia 2010;48: 529-535.
17. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. App Psychol Meas 1977;1: 89-99.
18. Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 2006;28: 1095-1112.
19. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24: 165-178.
20. Gogos A, Gavrilescu M, Davison S, et al. Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: an fMRI study. Neuropsychologia 2009;48: 529-535.
21. Fu CHY, Morgan K, Suckling J, et al. A functional magnetic resonance imaging study of overt letter verbal fluency using a clustered acquisition sequence: greater anterior cingulate activation with increased task demand. Neuroimage 2002;17: 871-879.
22. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life Questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50: 209-221.
23. Friston KJ, Holmes AP, Worsley KJ. How many subjects constitute a study? Neuroimage 1999;10: 1-5.
24. Armitage P, Berry G. Statistical Methods Inmedical Research. 3rd ed. Oxford, England: Blackwell Scientific Publications, 1994.
25. Newhouse PA, Dumas J, Wilkins H, et al. Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women. Menopause 2010;17: 860-873.
26. Hogue CW Jr, Freedland K, Hershey T, et al. Neurocognitive outcomes are not improved by 17A-estradiol in postmenopausal women undergoing cardiac surgery. Stroke 2007;38: 2048-2054.
27. Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology 2009;73: 1729-1737.
28. Berent-Spillson A, Persad CC, Love T, et al. Hormonal environment affects cognition independent of age during the menopause transition. J Clin Endocrinol Metab 2012;97:E1686-E1694.
29. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17: 485-495.
30. LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS. Hot flashes and estrogen therapy do not influence cognition in early menopausal women. Menopause 2007;14: 191-202.
31. Dunkin J, Rasgon N, Wagner-Steh K, David S, Altshuler L, Rapkin A. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2005;30: 284-296.
32. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006;91: 1802-1810.
33. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, doubleblind trial. Neurology 2007;69: 1322-1330.
34. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 2009;34: 1065-1074.
35. Berent-Spillson A, Persad CC, Love T, et al. Early menopausal hormone use influences brain regions used for visual working memory. Menopause 2010;17: 692-699.
36. Maki PM, Dennerstein L, Clark M, et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. Brain Res 2011;1379: 232-243.
37. Dumas JA, Kutz AM, Naylor MR, et al. Increased memory loadYrelated frontal activation after estradiol treatment in postmenopausal women. Horm Behav 2010;58: 929-935.
38. Smith YR, Love T, Persad CC, Tkaczyk A, Nichols TE, Zubieta JK. Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. J Clin Endocrinol Metab 2006;91: 4476-4481.
39. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995;761: 311-335.
40. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419-428.
41. Maruff P, Falleti MG, Collie A, Darby D, McStephen M. Fatiguerelated impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. J Sleep Res 2005; 14: 21-27.
42. Rossouw JE, Anderson GL, Prentice RL, et al Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.